Literature DB >> 1670925

Free intracellular Ca2+ concentration ([Ca2+]i) and growth hormone release from purified rat somatotrophs. II. Somatostatin lowers [Ca2+]i by inhibiting Ca2+ influx.

B T Lussier1, D A Wood, M B French, B C Moor, J Kraicer.   

Abstract

This study was carried out to investigate the role of Ca2+ in the somatostatin (SRIF)-induced inhibition of GH release. We examined the effect of SRIF on basal and GH-releasing factor (GRF)-induced increases in Ca2+ influx and free intracellular Ca2+ concentration ([Ca2+]i) in normal somatotrophs and examined the effect of SRIF on 45Ca uptake, [Ca2+]i measured with indo-1, and GH release. SRIF inhibited basal and GRF-induced GH release concurrently with a reduction in steady state 45Ca uptake. In nonsteady state experiments, SRIF also decreased basal 45Ca uptake. SRIF decreased baseline [Ca2+]i in a concentration-dependent manner and inhibited the GRF-induced biphasic increase in [Ca2+]i, but in a differential fashion. Low concentrations of SRIF abolished the peak (first phase) without affecting the plateau (second phase), while at high concentrations, both phases were inhibited. SRIF blocked the GRF-induced increase in [Ca2+]i regardless of whether it was applied before or during GRF stimulation. These data indicate that the SRIF-dependent decrease in 45Ca uptake is due to a decrease in Ca2+ influx. This is further supported by the fact that the GRF-dependent increase in [Ca2+]i, which is dependent on Ca2+ influx, is blocked by SRIF. The reported ability of SRIF to reduce the activation rate of Ca2+ currents, decrease Ca2+ conductance, and hyperpolarize the cell would explain the differential effect of SRIF on the GRF-induced [Ca2+]i increase. The inhibitory effect of SRIF on GH release would then be dependent on the ability of SRIF to decrease, or prevent, an increase in [Ca2+]i.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670925     DOI: 10.1210/endo-128-1-583

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Growth hormone-releasing hormone triggers pacemaker activity and persistent Ca2+ oscillations in rat somatotrophs.

Authors:  R Kwiecien; V Tseeb; A Kurchikov; C Kordon; C Hammond
Journal:  J Physiol       Date:  1997-03-15       Impact factor: 5.182

Review 2.  Ion channels and signaling in the pituitary gland.

Authors:  Stanko S Stojilkovic; Joël Tabak; Richard Bertram
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

3.  Somatostatin activates an inwardly rectifying K+ conductance in freshly dispersed rat somatotrophs.

Authors:  S M Sims; B T Lussier; J Kraicer
Journal:  J Physiol       Date:  1991-09       Impact factor: 5.182

4.  Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells.

Authors:  C Petrucci; D Cervia; M Buzzi; C Biondi; P Bagnoli
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

5.  Expression of Ca(2+)-mobilizing endothelin(A) receptors and their role in the control of Ca(2+) influx and growth hormone secretion in pituitary somatotrophs.

Authors:  M Tomić; D Zivadinovic; F Van Goor; D Yuan; T Koshimizu; S S Stojilkovic
Journal:  J Neurosci       Date:  1999-09-15       Impact factor: 6.167

6.  Neuronostatin is co-expressed with somatostatin and mobilizes calcium in cultured rat hypothalamic neurons.

Authors:  S L Dun; G C Brailoiu; A A Tica; J Yang; J K Chang; E Brailoiu; N J Dun
Journal:  Neuroscience       Date:  2010-01-04       Impact factor: 3.590

Review 7.  Dependence of the excitability of pituitary cells on cyclic nucleotides.

Authors:  S S Stojilkovic; K Kretschmannova; M Tomić; C A Stratakis
Journal:  J Neuroendocrinol       Date:  2012-09       Impact factor: 3.627

8.  Butyrate increases intracellular calcium levels and enhances growth hormone release from rat anterior pituitary cells via the G-protein-coupled receptors GPR41 and 43.

Authors:  Maria Consolata Miletta; Vibor Petkovic; Andrée Eblé; Roland A Ammann; Christa E Flück; Primus-E Mullis
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.